Maat Pharma SA
PAR:MAAT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
M
|
Maat Pharma SA
PAR:MAAT
|
FR |
|
Y
|
Ypsomed Holding AG
XBER:OWX
|
CH |
|
Steadfast Group Ltd
OTC:SFGLF
|
AU |
|
Caixabank SA
F:48CA
|
ES |
|
T
|
Toyota Industries Corp
F:TAH0
|
JP |
|
Ambev SA
BOVESPA:ABEV3
|
BR |
|
APA Group
OTC:APAJF
|
AU |
|
O
|
Oil States International Inc
XBER:OI2
|
US |
|
B
|
Bayan Resources Tbk PT
XMUN:BNB
|
ID |
|
O
|
OSE Immunotherapeutics SA
LSE:0RAD
|
FR |
|
G
|
GMK Noril'skiy Nikel' PAO
VSE:MNOD
|
RU |
|
T
|
Telefonaktiebolaget LM Ericsson
DUS:ERCB
|
SE |
|
Bridgestone Corp
F:BGT
|
JP |
|
Ritchie Bros Auctioneers Inc
TSX:RBA
|
CA |
|
Z
|
Zijin Mining Group Co Ltd
XMUN:FJZ
|
CN |
|
R
|
Rhoen Klinikum AG
DUS:RHK
|
DE |
|
Nippon Television Holdings Inc
F:NP9
|
JP |
Wall St Price Targets
MAAT Price Targets Summary
Maat Pharma SA
According to Wall Street analysts, the average 1-year price target for MAAT is 12.24 EUR with a low forecast of 3.03 EUR and a high forecast of 17.85 EUR.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is MAAT's stock price target?
Price Target
12.24
EUR
According to Wall Street analysts, the average 1-year price target for MAAT is 12.24 EUR with a low forecast of 3.03 EUR and a high forecast of 17.85 EUR.
What is the Revenue forecast for Maat Pharma SA?
Projected CAGR
177%
The compound annual growth rate for Revenue over the next 3 years is 177%.
What is the Gross Profit forecast for Maat Pharma SA?
Projected CAGR
193%
The compound annual growth rate for Gross Profit over the next 2 years is 193%.
